Ligand id: 7685

Name: mepolizumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: mepolizumab

Immunopharmacology Comments
IL-5 is a major driver of eosinophil growth, differentiation, recruitment, activation, and survival and is considered an important factor in asthma pathogenesis [4]. Mepolizumab-mediated neutralisation of IL-5 activity leads to a reduction in eosinophil numbers in blood, tissue and sputum and this effect underlies the drug's anti-inflammatory action. Nucala® became the first respiratory biologic to be authorised for self-administration [1], following FDA approval of autoinjector and pre-filled safety syringe versions of the drug in June 2019.
Immunopharmacology Disease
Disease X-Refs Comment References
Asthma Disease Ontology: DOID:2841
OMIM: 600807
Approved therapeutic for severe eosinophilic asthma.
Hypereosinophilic syndrome, idiopathic; HES OMIM: 607685
Orphanet: ORPHA3260
FDA and EMA orphan therapy for hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis (also known as Churg-Strauss syndrome or allergic granulomatosis).